Brian Thomas, Metagenomi CEO
No introductions necessary: A TCR upstart with deep-pocket backers partners with one of the new players in the hot gene editing field
When Affini-T arrived on the scene a few weeks ago, it had most of the essential elements needed by any biotech upstart.
There were high …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
